Terms ending in 2038
Every in-force patent on Precision Biosciences, Inc.'s record whose computed term ends in 2038, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 10,745,665 | Nucleic Acid Molecules Encoding an Engineered Antigen Receptor and an Inhibitory Nucleic Acid Molecule and Methods of Use Thereof In force · High confidence | Precision Biosciences, Inc. | In force | High confidence | |
| US 11,482,037 | User Interface Display Method of Terminal, and Terminal In force · High confidence | Huawei Technologies Co., Ltd. | In force | High confidence | |
| US 11,053,484 | Genetically-Modified T Cells Comprising a Modified Intron in the T Cell Receptor Alpha Gene In force · High confidence | Precision Biosciences, Inc. | In force | High confidence | |
| US 12,448,613 | Genetically-Modified T Cells Comprising a Modified Intron in the T Cell Receptor Alpha Gene In force · High confidence | Precision Biosciences, Inc. | In force | High confidence | |
| US 12,595,470 | Engineered Nucleases That Target Human and Canine Factor VIII Genes as a Treatment for Hemophilia A In force · Medium confidence | Precision Biosciences, Inc. | In force | Medium confidence |
5 of 5 patents shown. Soonest term end first, then patent number.
4 of these are in force and held by Precision Biosciences, Inc..
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.